Leuven, Belgium, [May 4th 2020] On May 1st, INNODIA, a public/private partnership for research aiming at biomarker discovery and prevention of type 1 diabetes in Europe, won a €12m grant from the European Commission’s Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU). The additional funding will allow the consortium to deepen its search for new biomarkers in type 1 diabetes and to start clinical trials.
Building on the strong foundations of INNODIA, with its unique, Europe-wide clinical and basic research network for the study of type 1 diabetes (T1D), INNODIA HARVEST presents an ambitious program, which aims to consolidate the INNODIA clinical network as the reference point for conducting clinical studies to prevent or arrest T1D via focused objectives targeting consolidation and innovation.
For Prof. Chantal Mathieu, Coordinator of INNODIA, this grant represents a recognition of the quality of the research undertaken since INNODIA’s inception – and will provide the resources to take the project to the next level:
“INNODIA HARVEST gives the INNODIA consortium a great boost to fortify our European network in these uncertain times where the COVID-19 epidemic threatens to isolate us. Through INNODIA HARVEST we can stand united and work towards prevention of T1D”.